National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Trametinib (Mekinist®)

Mekinist® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Rapid Review

Commenced Completed Outcome
27/11/2015 22/12/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
27/07/2016  15/03/2017 Reimbursement Not Recommended at the Submitted Price.


The HSE has approved reimbursement following confidential price negotiations; April 2018.